Comparative Pharmacology
Head-to-head clinical analysis: BOSULIF versus GLEEVEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSULIF versus GLEEVEC.
BOSULIF vs GLEEVEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bosutinib is a tyrosine kinase inhibitor that targets BCR-ABL kinase, as well as SRC family kinases. It inhibits the phosphorylation of tyrosine residues in proteins involved in the BCR-ABL signaling pathway, thereby inhibiting cell proliferation and inducing apoptosis in Philadelphia chromosome-positive (Ph+) leukemia cells.
Imatinib mesylate is a tyrosine kinase inhibitor that selectively inhibits BCR-ABL, c-KIT, PDGFR, and other kinases, blocking proliferation and inducing apoptosis in cells expressing these targets.
400 mg orally once daily with food.
400 mg orally once daily with a meal and a large glass of water. For advanced GIST, 400 mg daily; for CML in chronic phase, 400 mg daily; for accelerated phase or blast crisis, 600 mg daily. Dose may be increased to 600 mg or 800 mg daily in patients with disease progression.
None Documented
None Documented
The terminal elimination half-life is approximately 22.5 hours (range 15-34 hours) following a 500 mg oral dose. This supports once-daily dosing, with steady-state achieved within 15 days.
Terminal elimination half-life is approximately 18 hours (range 13–20 hours) in healthy subjects; for the active N-desmethyl metabolite, half-life is about 40 hours (range 30–50 hours). Clinical context: Steady-state is achieved within 1–2 weeks; once-daily dosing maintains therapeutic concentrations.
Primarily fecal (approximately 85% of the administered dose), with renal excretion accounting for less than 1% as unchanged drug and 3% as metabolites. Biliary excretion is a significant route for elimination of unchanged drug and metabolites.
Primarily fecal (68% of dose) as metabolites; renal excretion accounts for approximately 13% of dose (predominantly as metabolites). Unchanged imatinib in urine is <10%.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor